Bupivacaine Liposome Injection
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Local Analgesia Via Infiltration
Conditions
Local Analgesia Via Infiltration
Trial Timeline
May 21, 2024 → Oct 12, 2026
NCT ID
NCT06344091About Bupivacaine Liposome Injection
Bupivacaine Liposome Injection is a approved stage product being developed by Jiangsu Hengrui Medicine for Local Analgesia Via Infiltration. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06344091. Target conditions include Local Analgesia Via Infiltration.
What happened to similar drugs?
5 of 20 similar drugs in Local Analgesia Via Infiltration were approved
Approved (5) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06344091 | Approved | Recruiting |
Competing Products
20 competing products in Local Analgesia Via Infiltration